These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 14004979)

  • 1. [Clinical and biological efficacy of a spirolactone in the treatment of various water-salt retentions].
    WAREMBOURG H; LINQUETTE M; LEKIEFFRE J; FOSSATI P
    Lille Med; 1961; 6():668-71. PubMed ID: 14004979
    [No Abstract]   [Full Text] [Related]  

  • 2. [Initial results in the spirolactone treatment of 2 cases of the edematous syndrome with secondary aldosteronism].
    DULAC JF; OUGIER J; DOURY P; BEN-ZENOU A; WEIL B
    Bull Mens Soc Med Mil Fr; 1960 Dec; 54():332-5. PubMed ID: 13724900
    [No Abstract]   [Full Text] [Related]  

  • 3. [Diuretic properties of a spirolactone].
    SCHWARTZ J; BLOCH R
    Strasb Med; 1961 Feb; 12():103-13. PubMed ID: 13749099
    [No Abstract]   [Full Text] [Related]  

  • 4. The 45-year story of the development of an anti-aldosterone more specific than spironolactone.
    Ménard J
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):45-52. PubMed ID: 15134800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions of high salt intake and the response of the cardiovascular system to aldosterone.
    Conlin PR
    Cardiol Rev; 2005; 13(3):118-24. PubMed ID: 15831143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drospirenone and its antialdosterone properties.
    Genazzani AR; Mannella P; Simoncini T
    Climacteric; 2007 Feb; 10 Suppl 1():11-8. PubMed ID: 17364593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Aldosterone blockade in essential hypertension].
    Venco A; Grandi AM
    Ital Heart J; 2005 May; 6 Suppl 1():34S-42S. PubMed ID: 15945298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties.
    Rübig A
    Climacteric; 2003 Oct; 6 Suppl 3():49-54. PubMed ID: 15018248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldosterone and cardiovascular pathology: from bench to bedside.
    Vintilă M; Băluţă M
    Rom J Intern Med; 2004; 42(1):15-26. PubMed ID: 15529592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldosterone antagonists: effective add-on therapy for the treatment of resistant hypertension.
    Gaddam KK; Pratt-Ubunama MN; Calhoun DA
    Expert Rev Cardiovasc Ther; 2006 May; 4(3):353-9. PubMed ID: 16716096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Aldosterone and kidney damage: clinical implications].
    Del Vecchio L; Sitia S
    G Ital Nefrol; 2009; 26(3):347-54. PubMed ID: 19554532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage.
    Fiebeler A; Nussberger J; Shagdarsuren E; Rong S; Hilfenhaus G; Al-Saadi N; Dechend R; Wellner M; Meiners S; Maser-Gluth C; Jeng AY; Webb RL; Luft FC; Muller DN
    Circulation; 2005 Jun; 111(23):3087-94. PubMed ID: 15939810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldosterone receptor antagonism in heart failure.
    Jennings DL; Kalus JS; O'Dell KM
    Pharmacotherapy; 2005 Aug; 25(8):1126-33. PubMed ID: 16207104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology of different progestogens: the special case of drospirenone.
    Sitruk-Ware R
    Climacteric; 2005 Oct; 8 Suppl 3():4-12. PubMed ID: 16203650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of disease: The role of aldosterone in kidney damage and clinical benefits of its blockade.
    Del Vecchio L; Procaccio M; Viganò S; Cusi D
    Nat Clin Pract Nephrol; 2007 Jan; 3(1):42-9. PubMed ID: 17183261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldosterone, mineralocorticoid receptors and vascular inflammation.
    Funder JW
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):263-9. PubMed ID: 15134827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of aldosterone antagonists in resistant hypertension.
    Calhoun DA
    Prog Cardiovasc Dis; 2006; 48(6):387-96. PubMed ID: 16714158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aldosterone and progression of kidney disease.
    Cortinovis M; Perico N; Cattaneo D; Remuzzi G
    Ther Adv Cardiovasc Dis; 2009 Apr; 3(2):133-43. PubMed ID: 19171691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldosterone receptor antagonism and heart failure: insights from an outpatient clinic.
    Mariotti R; Borelli G; Coceani M; Zingaro S; Barison A; Morelli I; Rondinini L
    J Clin Pharm Ther; 2008 Aug; 33(4):349-56. PubMed ID: 18613852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular benefits of aldosterone receptor antagonists.
    Williams GH
    Climacteric; 2003 Oct; 6 Suppl 3():29-35. PubMed ID: 15018246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.